Study protocol for locoregional precision treatment of hepatocellular carcinoma with transarterial chemoembolisation (TACTida), a clinical study: idarubicin dose selection, tissue response and survival

INTRODUCTION: Hepatocellular carcinoma (HCC) is a common cause of cancer-related death, often detected in the intermediate stage. The standard of care for intermediate-stage HCC is transarterial chemoembolisation (TACE), where idarubicin (IDA) is a promising drug. Despite the fact that TACE has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Nyman, Sofi Sennefelt, Ahlström, Håkan, Creusen, Angeliki Dimopoulou, Dahlgren, David, Hedeland, Mikael, Heindryckx, Femke, Johnson, Ulf, Khaled, Jaafar, Kullenberg, Fredrik, Nyman, Rickard, Rorsman, Fredrik, Sheikhi, Reza, Simonsson, Ulrika S H, Sjögren, Erik, Wanders, Alkwin, Lennernäs, Hans, Ebeling Barbier, Charlotte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644353/
https://www.ncbi.nlm.nih.gov/pubmed/36343995
http://dx.doi.org/10.1136/bmjopen-2022-065839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644353/
https://www.ncbi.nlm.nih.gov/pubmed/36343995
http://dx.doi.org/10.1136/bmjopen-2022-065839

Ejemplares similares